SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

1 marketing jobs

CSL logo
4 weeks ago

Area Manager-Specialty Fort Worth TX

CSL

USA (Unknown)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
CSL logo

Area Manager-Specialty Fort Worth TX

CSL

USA (Unknown)

In-houseFull-timeMid level5+ years exp.
4 weeks ago
CSL logo
CSL

Area Manager-Specialty Fort Worth TX

USA (Unknown)

Salary Not AvailableMid Level5+ years expFull time

Posted 4 weeks ago

  • Job
  • Company
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own and drive CSL product promotion and distributor management to meet sales targets, while developing key accounts and contributing to marketing strategy.

  • Manage field sales and distribution networks to achieve territory targets.
  • Develop and maintain relationships with key accounts and KOLs.
  • Support education programs and provide input to marketing strategy.

Job Description

Responsibilities

  • Responsible for promotion of CSL products and managing business development/distributors to achieve sales targets
  • Promotes products to select call points to achieve territory sales targets, consistent with regional/corporate direction
  • Develops and maintains relationships with key accounts and external clients to increase awareness of product offerings; establishes and maintains high level scientific relationships with KOL key opinion leaders
  • Facilitates development of new accounts while supporting growth of existing accounts
  • Supports education programs, providing presentations at scientific congresses, conferences and patient organization meetings
  • Provides input to the marketing strategy
  • Ensures customer contact and promotional activities comply with company policy and standard operating procedures

Requirements

  • Bachelor degree in a scientific or business field
  • 5+ years' experience in pharmaceutical sales
  • Demonstrated success with field sales and market share growth
  • Knowledge of the pharmaceutical market and regulations
CSL logo

CSL

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.See our community guidelines: https://bit.ly/3Bs17Ra

Founded in 1916
Carlton, Victoria, AUS
23K employees (629 in marketing)
www.csl.com

Marketing Team

Marketing Team Size
547 (2% of company)
Median Career Experience
18 years
Median Tenure
5 years
Marketing Roles Posted (Last 30 Days)
1

People

HR / Recruitment

Elise Neef
Elise Neef
Associate Director, Talent Marketing & Programs
At the company for 4 years 8 months

Marketing Leadership

Christopher Borek
Christopher Borek
Head of Global Marketing
At the company for 2 years 4 months
Sharad Agrawal
Sharad Agrawal
Head of Global Marketing, Hematology
At the company for 9 years 7 months
Kyler Nuzzo
Kyler Nuzzo
Associate Director, Marketing
At the company for 4 years 5 months
Jennifer M.
Jennifer M.
Immunology Marketing Director
At the company for 1 year 2 months

Funding

Total Funding
$111M
Last Raise
$111M
Post IPO Equity, 22 years ago

Funding History

  • Feb 2004
    Post IPO Equity • $111M

Traffic Signals

Monthly Visitors
150.4K
Traffic Source Mix
Search
55.8%
Direct
33.6%
Referral
7.5%
Social
1.8%
Paid
1.1%

Headcount Trend

Current headcount: ~23.5K

Recent News

Why CSL might be undervalued right now
Oct 8, 2025 • moneymag.com.au
CSL stock has been falling: bargain or beware?
Oct 4, 2025 • The Motley Fool Australia
CSL shares: Buy, sell or hold?
Oct 2, 2025 • The Motley Fool Australia
Why did CSL shares sink again in September?
Oct 1, 2025 • The Motley Fool Australia
Is now the time to load up on CSL shares?
Sep 30, 2025 • The Motley Fool Australia
Trump tariff announcement wipes $1bn from CSL value – as it happened
Sep 26, 2025 • The Guardian
CSL shares fall on new Trump tariff hit
Sep 26, 2025 • The Motley Fool Australia
Stock Take: Deep Dive - CSL
Sep 26, 2025 • intelligentinvestor.com.au
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up
Sep 25, 2025 • simplywall.st
Allan Gray Buys CSL After Share Price Fall
Sep 24, 2025 • Sharecafe
Allan Gray adds CSL to $2.6b fund after a brutal August
Sep 23, 2025 • AFR
Buy CSL and these dirt cheap ASX 200 blue chip shares at 52-week lows
Sep 22, 2025 • The Motley Fool Australia
A deep dive into CSL shares
Sep 19, 2025 • Rask Media
Neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Sep 19, 2025 • MarketScreener
Health Check: CSL plucks up Dutch courage with R&D partnership worth about $755m
Sep 16, 2025 • Stockhead
CSL shares fall despite big news
Sep 16, 2025 • The Motley Fool Australia
CSL Shares (ASX: CSL) Plunge to 5-Year Low Amid Restructuring and Profit Concerns
Sep 16, 2025 • thebull.com.au
CSL makes $760m bet on Dutch biotech
Sep 16, 2025 • AFR
CSL (ASX:CSL) share price in focus on US$505 million partnership
Sep 16, 2025 • Rask Media
VarmX, an Ysios portfolio company, partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
Sep 16, 2025 • capital-riesgo.es
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
Sep 16, 2025 • PharmiWeb
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
Sep 16, 2025 • News Powered by Cision
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
Sep 16, 2025 • Business Wire
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
Sep 16, 2025 • Morningstar.com
By 2026, the CSL share price could turn $5,000 into…
Sep 14, 2025 • The Motley Fool Australia
After a horror month should you buy the dip on CSL shares?
Sep 11, 2025 • The Motley Fool Australia
Why is the CSL share price falling today?
Sep 9, 2025 • The Motley Fool Australia
Why VanEck Australia’s ETF has doubled down on its CSL short
Sep 8, 2025 • AFR
Explainer: What Is the CSL Behring Fermentation Facility at Penn State?
Sep 8, 2025 • Global Biotechnology Company
CSL shares: 5 analysts encouraging investors to buy the dip and why
Sep 4, 2025 • The Motley Fool Australia
A quick way to value the CSL share price
Sep 4, 2025 • Rask Media
CSL: Why I’m still holding
Sep 3, 2025 • Morningstar
Free Mark Cuban Foundation AI Bootcamp Coming to Philadelphia This Fall
Sep 3, 2025 • Mark Cuban Foundation
‘We have to fix this’: Brian McNamee on turning around CSL
Aug 31, 2025 • AFR
The CSL share price is at a 6-year low. Should you buy?
Aug 27, 2025 • The Motley Fool Australia
Forecast: Here's what $20,000 invested in CSL shares could be worth by 2030
Aug 25, 2025 • The Motley Fool Australia
Stock Tips: CSL battered and bloody, but for these experts it’s no time to sell
Aug 24, 2025 • Stockhead
Scott Power: ASX health sector falls almost 10pc with CSL absolutely battered
Aug 22, 2025 • Stockhead
Is the CSL share price dirt cheap after crashing this week?
Aug 21, 2025 • The Motley Fool Australia
CSL shareholders in shock as share price falls 15% in one day
Aug 20, 2025 • Rask Media
Are CSL shares a buy after the brutal selloff?
Aug 20, 2025 • The Motley Fool Australia
Health Check: CSL shares do another Humpty Dumpty, but experts say this bruised egg can be fixed
Aug 20, 2025 • Stockhead
CSL launches strategic initiatives with planned separation of Seqirus
Aug 20, 2025 • Biotech Dispatch
Health Check: CSL turns to a vaccines demerger in an ‘urgent’ get-fit drive
Aug 19, 2025 • Stockhead
CSL restructure fails to convince investors as shares plunge 17pc
Aug 19, 2025 • AFR
CSL profit beats forecasts but market reels from sweeping restructure
Aug 19, 2025 • Proactive financial news
CSL FY25 earnings: Revenue grows, Seqirus demerger ahead
Aug 19, 2025 • The Motley Fool Australia
CSL Shares Fall to Multi-Year Low – What Happened?
Aug 19, 2025 • thebull.com.au
CSL (ASX:CSL) share price sinks 16% on FY25 result, split-up plans
Aug 19, 2025 • Rask Media
VIDEO: CSL shares slump on profit results and demerger plan
Aug 19, 2025 • Australian Broadcasting Corporation
CSL crashes 15% in worst selloff since 1994 ASX listing
Aug 19, 2025 • Market Index
CSL to slash headcount by 15% and spinout its CSL Seqirus vaccines business
Aug 19, 2025 • European Pharmaceutical Review
CSL to cut 15% of global workforce in major restructure
Aug 19, 2025 • HRD America
CSL to cut 15% of workforce
Aug 19, 2025 • hrleader.com.au
CSL announces rise in full year net profit
Aug 18, 2025 • Morningstar.com
CSL announces rise in full year net profit
Aug 18, 2025 • PR Newswire UK
Italy Approves Reimbursement of Innovative Gene Therapy HEMGENIX® (etranacogene dezaparvovec) for Haemophilia B
Aug 1, 2025 • PharmiWeb
CSL downgraded to Hold
Jul 31, 2025 • intelligentinvestor.com.au
Why CSL shares are a buy today despite the looming Trump tariffs
Jul 24, 2025 • The Motley Fool Australia
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$439m
Jul 23, 2025 • Morningstar.com
CSL’s Plasma Fractionation Facility Wins Pharmaceutical Engineering Award
Jul 22, 2025 • Global Biotechnology Company
First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Germany
Jul 3, 2025 • PharmiWeb
Global Vaccines Market Set to Grow at 9.80% CAGR Amid Rising Demand for Digital Healthcare Solutions
Jun 19, 2025 • PharmiWeb
FDA green lights CSL's once-monthly HAE drug Andembry
Jun 17, 2025 • pharmaphorum
Blood Plasma Derivatives Market Expected to Reach USD 98.69 Billion by 2032, Growing at 9.3% CAGR
Jun 11, 2025 • EIN Presswire
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Jun 10, 2025 • Research and Markets
Albumin Market Set to Reach USD 11.02 Billion by 2032, Driven by Rising Therapeutic Applications and Expanding Healthcare Demand – SNS Insider
Jun 10, 2025 • SNS Insider pvt ltd
Australia shares cross 8,500 as oil lifts energy stocks; tech, healthcare shine
Jun 4, 2025 • Reuters
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market Sales
May 23, 2025 • Research and Markets
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 23, 2025 • MarketScreener
Global mRNA Vaccines and Therapeutics Market Set to Reach USD 850.9 Million by 2033 | DataM Intelligence
May 23, 2025 • EIN Presswire
Adult Vaccine Market Forecast Report 2025-2033: Increasing Geriatric Population and Immunosenescence, Increasing Government Vaccination Campaigns and Awareness, Advancements in Innovations
May 16, 2025 • Research and Markets
Longwood Healthcare Leaders to Convene Top Life Science E...
May 15, 2025 • PharmiWeb
Hereditary Angioedema Global Market Report 2025: Projections And Trends For The Global HAE Industry
May 14, 2025 • EIN Presswire
CSL names business development director
May 13, 2025 • Telecompaper
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 12, 2025 • BioSpace
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 12, 2025 • MarketScreener
Global pharma shares drop as Trump targets US drug prices
May 12, 2025 • MarketScreener
CSL Recruitment 2025 : Apply for Project Officer vacancy - Northeast Now
Apr 22, 2025 • Northeast Now - Our Land, Our News
Greg Olsen talks with CSL ahead of Super Bowl LIX
Apr 21, 2025 • Yahoo Sports
CSL Launches Andembry For Prevention Of Acute Attacks In Hereditary Angioedema In Japan
Apr 18, 2025 • marketscreener.com
Docker Vision Awarded Rs 1 cr Grant Under CSL’s USHUS Program
Apr 17, 2025 • News Experts
Pennsylvania Biotech: Combating Rare Diseases Worldwide
Apr 17, 2025 • PA Department of Community & Economic Development (.gov)
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi
Apr 17, 2025 • Barchart.com
Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines
Apr 9, 2025 • MarketScreener
Vaccines Market (2024-2035) – A Comprehensive Industry Analysis
Apr 7, 2025 • PharmiWeb
CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe's First Gene Therapy for Haemophilia B
Apr 3, 2025 • PharmiWeb
CSL’s Hemgenix gene therapy gains German reimbursement
Apr 3, 2025 • Pharma Letter
Miners, banks lift Australia shares higher; inflation eases
Mar 26, 2025 • MarketScreener
Miners, banks lift Australia shares higher; inflation eases
Mar 26, 2025 • TradingView
Mining stocks, banks lift Australian shares ahead of inflation data
Mar 25, 2025 • mint
Mining stocks, banks lift Australian shares ahead of inflation data
Mar 25, 2025 • MarketScreener
CSL Limited: Divergent Outlook For Its 2 Key Businesses
Mar 21, 2025 • Seeking Alpha
CSL Finance Initiates Postal Ballot for Shareholder Resolutions
Mar 21, 2025 • TipRanks
CSL initiated with an Overweight at Morgan Stanley
Mar 20, 2025 • Yahoo Finance
Shipbuilding stocks: GRSE, CSL, MDL shares rise up to 28% on BSE, here to know
Mar 20, 2025 • PSU Connect
Morgan Stanley initiates CSL stock with Overweight rating
Mar 19, 2025 • Investing.com India
CSL Recognized as One of Montreal's Top Employers for Seventh Consecutive Year
Mar 18, 2025 • Financial Post
CSL’s global operations enhance career prospects
Mar 18, 2025 • MSN
Short Interest in CSL Limited (OTCMKTS:CSLLY) Rises By 189.9%
Mar 18, 2025 • MarketBeat

Links

www.csl.comLinkedInX (Twitter)Crunchbase